JP2023544143A5 - - Google Patents
Info
- Publication number
- JP2023544143A5 JP2023544143A5 JP2023519492A JP2023519492A JP2023544143A5 JP 2023544143 A5 JP2023544143 A5 JP 2023544143A5 JP 2023519492 A JP2023519492 A JP 2023519492A JP 2023519492 A JP2023519492 A JP 2023519492A JP 2023544143 A5 JP2023544143 A5 JP 2023544143A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- variable region
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011054428 | 2020-09-29 | ||
| CN202011054428.6 | 2020-09-29 | ||
| PCT/CN2021/121286 WO2022068810A1 (zh) | 2020-09-29 | 2021-09-28 | 抗Claudin18.2和CD3的双特异性抗体以及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023544143A JP2023544143A (ja) | 2023-10-20 |
| JP2023544143A5 true JP2023544143A5 (cg-RX-API-DMAC7.html) | 2024-10-07 |
Family
ID=80949663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519492A Ceased JP2023544143A (ja) | 2020-09-29 | 2021-09-28 | 抗クローディン18.2および抗cd3二重特異性抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230357389A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4223778A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023544143A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230079165A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116323676A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021352532B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200865A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI837517B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022068810A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023245103A1 (en) * | 2022-03-28 | 2024-10-24 | Fortvita Biologics (Singapore) Pte. Ltd. | Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof. |
| CN117229398A (zh) * | 2022-06-15 | 2023-12-15 | 中山康方生物医药有限公司 | 抗cldn18.2抗体、其药物组合物及用途 |
| KR20240101987A (ko) * | 2022-12-23 | 2024-07-03 | 주식회사 와이바이오로직스 | 클라우딘-18.2에 특이적으로 결합하는 단클론항체 및 이의 용도 |
| CN116813782B (zh) * | 2023-08-10 | 2024-01-23 | 北京百普赛斯生物科技股份有限公司 | 一种Claudin-18.2特异性抗体及其应用 |
| WO2025162454A1 (zh) * | 2024-02-02 | 2025-08-07 | 北京昌平实验室 | 双特异性抗体和细胞因子融合蛋白及其应用 |
| CN120829517A (zh) * | 2024-04-22 | 2025-10-24 | 鲁南新时代生物技术有限公司 | 抗cldn18.2/cd3双特异性抗体及用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| EP2920209B1 (en) * | 2012-11-13 | 2020-08-05 | BioNTech SE | Agents for treatment of claudin expressing cancer diseases |
| IL282953B2 (en) * | 2012-11-13 | 2026-02-01 | Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh | Agents for the treatment of claudin-expressing cancers |
| BR112015010817A8 (pt) * | 2012-11-13 | 2018-01-23 | Genentech Inc | anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina |
| CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| SG11201905259SA (en) * | 2017-02-02 | 2019-08-27 | Merck Patent Gmbh | Preferred pairing of antibody domains |
| CA3053379A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| CN111247171A (zh) * | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| CA3098910A1 (en) * | 2018-05-01 | 2019-11-07 | Ambrx, Inc. | A method for optimizing antibody expression |
| EP3808376A4 (en) * | 2018-06-17 | 2021-09-01 | L&L Biopharma Co., Ltd. | CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF |
| BR112021002032A2 (pt) * | 2018-08-03 | 2021-07-20 | Amgen Research (Munich) Gmbh | construtos de anticorpos para cldn18.2 e cd3 |
-
2021
- 2021-09-28 CA CA3200865A patent/CA3200865A1/en active Pending
- 2021-09-28 KR KR1020237014540A patent/KR20230079165A/ko active Pending
- 2021-09-28 EP EP21874470.4A patent/EP4223778A4/en active Pending
- 2021-09-28 WO PCT/CN2021/121286 patent/WO2022068810A1/zh not_active Ceased
- 2021-09-28 US US18/246,939 patent/US20230357389A1/en active Pending
- 2021-09-28 AU AU2021352532A patent/AU2021352532B2/en not_active Expired - Fee Related
- 2021-09-28 CN CN202180066494.1A patent/CN116323676A/zh active Pending
- 2021-09-28 JP JP2023519492A patent/JP2023544143A/ja not_active Ceased
- 2021-09-28 TW TW110136039A patent/TWI837517B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11987635B2 (en) | Anti-4-1BB antibodies and methods of making and using thereof | |
| AU2018214223B2 (en) | Low pH pharmaceutical composition comprising T cell engaging antibody constructs | |
| JP6326137B2 (ja) | 抗her2抗体及びその結合体 | |
| CN106967172B (zh) | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| AU2018295119B2 (en) | Multi-specific antibodies and methods of making and using thereof | |
| JP2022533538A5 (cg-RX-API-DMAC7.html) | ||
| CN116396386A (zh) | Cd3抗体及其药物用途 | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2012518039A5 (cg-RX-API-DMAC7.html) | ||
| JP2022169504A5 (cg-RX-API-DMAC7.html) | ||
| JP6933724B2 (ja) | Nk細胞活性化融合タンパク質、nk細胞およびそれらを含む医薬組成物 | |
| AU2026202717A1 (en) | Anti c-met antibodies | |
| JP2025508317A5 (cg-RX-API-DMAC7.html) | ||
| RU2019121106A (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) | |
| CA3159155A1 (en) | Anti-clec-1a antibodies and antigen-binding fragment thereof | |
| JP2022502079A5 (cg-RX-API-DMAC7.html) | ||
| JP2025516590A5 (cg-RX-API-DMAC7.html) | ||
| CN114616245A (zh) | 一种抗cd38的抗体及其用途 | |
| US20250376531A9 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| WO2024131846A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| CA3304076A1 (en) | Bispecific antibodies that bind cd3 and the ganglioside ngcgm3 | |
| TW202612728A (zh) | 使用靶向表現her2之腫瘤之三特異性結合蛋白治療癌症之方法 | |
| HK40111323A (en) | Multi-specific antibodies and methods of making and using thereof |